Company Profile
Minerva Neuroscience Stock Price, News & Analysis
Company overview
Business overview
Minerva Neuroscience is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Minerva Neuroscience is followed within the biotech universe for its exposure to catalyst-driven execution.
Business Model Characteristics
Minerva Neuroscience follows a catalyst-driven model where the market watches how the company turns development work into repeatable value creation.
Position Within the Biotechnology Landscape
Compared with more mature healthcare peers, Minerva Neuroscience sits closer to the development side of the biotechnology landscape, where timing around data and approvals matters most.
Why the stock is moving
NERV is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Minerva Neurosciences’ catalysts are roluperidone and the negative-symptom schizophrenia program, where the next update could materially change the market’s view. The company still needs a clean clinical step.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates
Source: Minerva Neuroscience
- 02
Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company’s Board of Directors
Source: Minerva Neuroscience
- 03
- 04
Minerva Neurosciences to Participate in The Citizens Life Sciences Conference
Source: Minerva Neuroscience
- 05
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates
Source: Minerva Neuroscience
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.